Welcome to our dedicated page for SciSparc news (Ticker: SPRCY), a resource for investors and traders seeking the latest updates and insights on SciSparc stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SciSparc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SciSparc's position in the market.
SciSparc Ltd. (OTCQB: SPRCY) announced the approval from the Israeli Ministry of Health to initiate a Phase IIa Clinical Trial for SCI-110 in Alzheimer's disease patients experiencing agitation. The trial aims to evaluate the safety and efficacy of SCI-110, a unique formulation combining Dronabinol and CannAmide™, focusing on addressing agitation—a significant unmet need in AD treatment. Conducted under Dr. Alona Raveh, the study's outcomes could represent a crucial advancement, as current AG treatments are ineffective and generally entail off-label antipsychotic use.
SciSparc Ltd. (OTCQB: SPRCY) announced participation in the 31st Annual International Cannabinoid Research Society Symposium, scheduled for June 21-24, 2021, in Jerusalem, Israel. The company will sponsor an event honoring cannabinoid pioneer Prof. Raphael Mechoulam's 90th birthday. SciSparc focuses on cannabinoid-based treatments, aiming to leverage the 'entourage effect' to enhance drug efficiency and reduce side effects. The company is developing various drug candidates, including SCI-160 for pain management, featuring a CB2 receptor agonist developed by Mechoulam.
SciSparc Ltd. (OTCQB: SPRCY) announced a new agreement with The Sheba Fund for Health Services and Research to conduct a pre-clinical study on SCI-210, a novel drug combining cannabidiol (CBD) and palmitoylethanolamide (PEA). This study aims to evaluate SCI-210's efficacy against Status Epilepticus (SE) compared to CBD alone, leveraging the 'entourage effect' to potentially enhance treatment outcomes. The company highlights past efficacy of SCI-210 over CBD in preliminary tests and expresses optimism regarding improved safety and effectiveness for patients suffering from SE.
SciSparc Ltd. (OTCQB: SPRCY), a clinical-stage pharmaceutical company in Tel Aviv, announced the closure of a private placement, raising approximately $8.15 million. The offering involved selling 1,152,628 Units to accredited investors, including 916,316 units at $7.07 per unit and 236,312 pre-funded units at $7.069 per unit. The proceeds will support SciSparc's cannabinoid-based drug development programs, particularly for conditions like Tourette syndrome, pain, and autism. Aegis Capital Corp. served as the exclusive placement agent.
SciSparc Ltd. (OTCQB: SPRCY) has announced a private placement of 1,152,628 Units at $7.07 each, projected to raise approximately $8.15 million before expenses. Each Unit includes an American Depositary Share and two types of Warrants, with differing exercise prices. The offering is set to close on or around March 4, 2021, pending customary conditions. Aegis Capital Corp. is the exclusive placement agent. The securities are not registered under U.S. law, and the company plans to file a resale registration statement with the SEC.
SciSparc Ltd. (OTCQB: SPRCY) has entered an agreement with The Israeli Medical Center for Alzheimer's to begin a Phase IIa clinical trial evaluating the safety and efficacy of SCI-110 in Alzheimer’s patients exhibiting agitation. The principal objective focuses on the drug's safety, while secondary goals aim to assess its ability to alleviate agitation in these patients. The trial is expected to start promptly upon receiving necessary regulatory approvals. SCI-110 combines Dronabinol and Palmitoylethanolamide, targeting a market with inadequate current treatment options.
SciSparc Ltd. (OTCQB: SPRCY), formerly Therapix Biosciences, has announced a rebranding initiative effective February 2021. This includes a new company name, logo, and share symbol, aimed at realigning with its strategic focus on cannabinoid-based therapies. The company has partnered with Procaps for the development of drug candidates in softgel form, including SCI-110 and CannAmide™, which will be marketed in Canada. Additionally, the clinical programs have been renamed to reflect their focus on treating various central nervous system diseases and symptoms.